

(51) International Patent Classification:  
*A61K 9/00* (2006.01)**Lawrence**; 2416 Carmaria Court, North Vancouver, British Columbia, V7J 3M4 (CA).(21) International Application Number:  
PCT/US2016/042330(74) Agents: **MURASHIGE, Kate, H.** et al.; Morrison & Foester LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US).(22) International Filing Date:  
14 July 2016 (14.07.2016)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:  
62/192,973 15 July 2015 (15.07.2015) US  
62/252,396 6 November 2015 (06.11.2015) US(71) Applicant: **CELATOR PHARMACEUTICALS, INC.** [US/US]; 200 Pricetonsouth Corporate Center, Suite 180, Ewing, NJ 08628 (US).(72) Inventors: **WAN, Leon**; 6925 Dow Avenue, Burnaby, British Columbia, V5J 3X1 (CA). **LUI, Winnie**; 9371 Hemlock Drive, Apt. 117, Richmond, British Columbia, V6Y 4K6 (CA). **TARDI, Paul**; 19081 Sundale Court, Surrey, British Columbia, V3S 7M6 (CA). **MAYER,**

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,

[Continued on next page]

(54) Title: IMPROVED NANOPARTICLE DELIVERY SYSTEMS

Prodrugs of Docetaxel and AUY922 formulated in PLGA-PEG nanoparticles at a 1:2 drug ratio



Note: lowest free drug combination dose using 10 mg/kg docetaxel was excessively toxic (&gt;25% body wt loss)

Figure 3

(57) Abstract: Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.



---

LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, **Published:**  
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with international search report (Art. 21(3))*  
GW, KM, ML, MR, NE, SN, TD, TG).